Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, EQL Pharma AB's Enterprise Value is kr1,082.0 Mil.
EQL Pharma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was kr48.7 Mil. Therefore, EQL Pharma AB's EV-to-EBIT ratio for today is 22.22.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, EQL Pharma AB's Enterprise Value is kr1,082.0 Mil.
EQL Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr48.7 Mil. Therefore, EQL Pharma AB's EV-to-EBITDA ratio for today is 22.22.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, EQL Pharma AB's Enterprise Value is kr1,082.0 Mil.
EQL Pharma AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was kr432.7 Mil. Therefore, EQL Pharma AB's EV-to-Revenue ratio for today is 2.50.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, EQL Pharma AB's Enterprise Value is kr1,082.0 Mil.
EQL Pharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr-39.4 Mil. Therefore, EQL Pharma AB's EV-to-FCF ratio for today is -27.50.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
EQL Pharma AB (OSTO:EQL) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
EQL Pharma AB's current Enterprise Value is kr1,082.0 Mil.
EQL Pharma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr48.7 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
EQL Pharma AB's current Enterprise Value is kr1,082.0 Mil.
EQL Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr48.7 Mil.
EQL Pharma AB's current Enterprise Value is kr1,082.0 Mil.
EQL Pharma AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr432.7 Mil.
EQL Pharma AB's current Enterprise Value is kr1,082.0 Mil.
EQL Pharma AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr28.4 Mil.
EQL Pharma AB's current Enterprise Value is kr1,082.0 Mil.
EQL Pharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-39.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EQL Pharma AB Enterprise Value Related Terms
EQL Pharma AB Enterprise Value Historical Data
* Premium members only.
The historical data trend for EQL Pharma AB's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:EQL vs ZTS, UTHR: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EQL Pharma AB Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's Enterprise Value distribution charts can be found below:
* The bar in red indicates where EQL Pharma AB's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EQL Pharma AB's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of kr1,082.0 Mil mean?
EQL Pharma AB (OSTO:EQL) has a Enterprise Value of kr1,082.0 Mil as of Jul. 03, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on EQL Pharma AB and its competitors.
Is EQL Pharma AB's Enterprise Value too high?
EQL Pharma AB's current Enterprise Value is kr1,082.0 Mil. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's Enterprise Value compare to ZTS and UTHR?
EQL Pharma AB's Enterprise Value of kr1,082.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on EQL Pharma AB and its competitors. EQL Pharma AB's current Enterprise Value is kr1,082.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current Enterprise Value of kr1,082.0 Mil. The current Enterprise Value is kr1,082.0 Mil. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current Enterprise Value is kr1,082.0 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
42GF Score
Get the complete analysis for OSTO:EQL
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EQL has been successfully added to your 
